Erasca Advances RAS Therapies Toward Phase 1 Data

Erasca, Inc. (ERAS), a clinical-stage biotech focused on RAS/MAPK-driven cancers, is advancing its two lead assets—ERAS-0015 and ERAS-4001—into Phase 1 monotherapy trials after IND clearance, with Phase 1 data expected in 2026. The company reported a cash runway into H2 2028 (potentially 2029 after recent offerings) and no revenue, presenting high binary clinical and funding risks.